HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martín-Campos, J. M. Articles by Blanco-Vaca, F. Search for Related Content PubMed PubMed Citation Articles by Martín-Campos, J. M. Articles by Blanco-Vaca, F. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 43, 115-123, January 2002
Copyright © 2002 by Lipid Research, Inc.

ApoA-I_MALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia

Correspondence to: Francisco Blanco-Vaca, at Hospital de la Santa Creu i Sant Pau, Servei de Bioquímica, C/Antoni M Claret 167, 0825 Barcelona, Spain., fblancova{at}hsp.santpau.es (E-mail)

Apolipoprotein (apo)A-I is the major protein component of HDL and the cofactor for LCAT. We describe a large Spanish kindred, living in the Mediterranean Island of Mallorca, that presents a dominant form of hypoalphalipoproteinemia. The lipid profile of this family was studied because the proband, a 40-year-old male presenting signs of coronary atherosclerosis, showed severe HDL deficiency. However, none of the other family members had a known history of cardiovascular disease. Sequence analysis of the apoA-I gene in affected members identified a 33-base pair deletion, corresponding to residues 165–175 of the mature protein, eliminating the first 11 amino acids of the internal repeat 7. ApoA-I_MALLORCA is associated with HDL-cholesterol deficiency (concentration ranging from 8–48% of the value in non-carriers), and a 2- to 3-fold decrease in plasma concentrations of apoA-I and apoA-II and endogenous LCAT activity, concomitant with a slight decrease in serum cholesterol efflux capability. Impairment of LCAT activity in HDL particles containing only mutated forms of apoA-I would not explain a pattern of dominant inheritance. HDL particles containing wild type apoA-I and at least one mutant apoA-I may also present impaired LCAT activity and/or other alterations leading to defective HDL maturation, a situation that would increase HDL lipid catabolism.

We conclude that amino acids 165–175 of apoA-I are critical for normal HDL metabolism, at least in part because of their role in LCAT activation. However, apoA-I_MALLORCA is not necessarily associated with clinical signs of atherosclerosis. — Martín-Campos, J. M., J. Julve, J. C. Escolà, J.Ordóñez-Llanos, J. Gómez, J. Binimelis, F. González-Sastre, and F. Blanco-Vaca. ApoA-I_MALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia. J. Lipid Res. 2002. 43: 115–123.

Supplementary key words: apolipoprotein, atherosclerosis, coronary heart disease, high density lipoprotein, molecular diagnosis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Ferre, J. Camps, J. Marsillach, B. Mackness, M. Mackness, B. Coll, M. Tous, and J. Joven Comparison of Paraoxonase 1 Measurements in Serum and in Lithium-Heparin-Anticoagulated Plasma Samples Clin. Chem., May 1, 2005; 51(5): 922 - 923. [Full Text] [PDF]

				M. S. Spagnuolo, L. Cigliano, L. D. D'Andrea, C. Pedone, and P. Abrescia Assignment of the Binding Site for Haptoglobin on Apolipoprotein A-I J. Biol. Chem., January 14, 2005; 280(2): 1193 - 1198. [Abstract] [Full Text] [PDF]